Resverlogix Corp.: Resverlogix Announces New Research Highlighting Apabetalone's Potential Benefits in Cardiovascular Disease, Heart Failure, and COVID-19
Calgary, Alberta--(Newsfile Corp. - March 2, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced the publication of two articles in peer-reviewed scientific journals. The first, entitled
United States Dennis Riedl Ewelina Kulikowski International Immunopharmacology American College Of Cardiology World Heart Federation
Source: finanznachrichten.de